![Shunichi Ishimura](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shunichi Ishimura
Voorzitter bij THANN Natural KK
Oorsprong van het eerstegraads netwerk van Shunichi Ishimura
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Path Imaging KK
![]() Path Imaging KK Medical SpecialtiesHealth Technology Path Imaging KK engages in the development, manufacture and sale of medical equipment. The company was founded in October 2014 and is headquartered in Hiromae, Japan.
3
| Holding Company | Medical Specialties | 3 |
Public Company | Industrial Machinery | 1 | |
THANN Natural KK
1
| Private Company | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Shunichi Ishimura via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
METAREAL CORPORATION | Packaged Software | Director/Board Member | |
J & I YK | Director/Board Member | ||
Kobe University Graduate School of Business Administration | College/University | Undergraduate Degree | |
YES-fm KK | Comptroller/Controller/Auditor | ||
C.H.C. SYSTEM Co., Ltd. | Director/Board Member | ||
HuBit Genomix KK
![]() HuBit Genomix KK Miscellaneous Commercial ServicesCommercial Services HuBit Genomix KK is a Japanese pharmaceutical development company that conducts clinical trials and research on pharmaceuticals to develop diagnostic drugs. The company is based in Tokyo, Japan. The company analyzes and utilize valuable information to create "diagnosis methods" and "pharmaceuticals" that satisfy medical amenities. HuBit Genomix KK was acquired by Celera Group on March 20, 2001. | Miscellaneous Commercial Services | Director/Board Member | |
BioComo, Inc.
![]() BioComo, Inc. BiotechnologyHealth Technology BioComo, Inc. is a biotech company founded in Mie Prefecture, Japan in 2008. The private company is developing cutting-edge technology platforms for creating novel vaccine carriers and adjuvants to enhance immunity in collaboration with the microbiology and molecular genetics department of Mie University. The Japanese company's technology has already succeeded in the development of highly efficacious and state-of-the-art vaccine carrier and novel adjuvant candidates. The company's technology will be applied to the production of the next generation vaccines for the prevention of infections such as RS virus, Ebola virus, influenza virus, and SARS-CoV-2, enabling faster and cost-effective production of those vaccines. BC-PIV is the core platform technology which was named after the corporate name, BioComo, and the leading vaccine carrier which is derived from the recombinant human parainfluenza virus 2 (HPIV2) vectors. | Biotechnology | Director/Board Member | |
Development Association For Youthleaders | Director/Board Member |
Statistieken
Internationaal
Japan | 8 |
Duitsland | 2 |
Sectoraal
Technology Services | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Health Technology | 2 |
Operationeel
Director/Board Member | 11 |
President | 2 |
Comptroller/Controller/Auditor | 2 |
Founder | 1 |
Undergraduate Degree | 1 |
Sterkste connecties
Insiders | |
---|---|
Hiroki Hidejima | 9 |
Masashi Sugawara | 2 |
Hideaki Kobayashi | 2 |
Tamotsu Sato | 1 |
- Beurs
- Insiders
- Shunichi Ishimura
- Bedrijfsconnecties